As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

WASHINGTON — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients — revving up their immune systems to help fight tumors. People with advanced lung or skin ...

MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual property developed by Monsanto, the crop science company the German company ...

Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, U.S. health officials said Thursday. The strange ...

A Moderna spokesperson said the company is aware of the lawsuit and will defend itself. Spokespeople for Pfizer, BioNTech and Johnson & Johnson did not immediately respond to requests for comment.

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

An update from Moderna ( (MRNA)) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating environment in the U.S. but highlighted strong execution ...